A mesenchymal phenotype with an upregulation of vimentin and downregulation of epithelial markers (E-cadherin and occludin) was obtained in breast cancer cells with stable or transient silencing of Elovl5 expression as assessed at 48 h by western blotting (Fig. 7A) and RT-qPCR (Fig. 7B) while the treatment with DGAT inhibitors (DGAT1i and DGAT2i) reversed the EMT triggered by Elovl5 extinction in breast cancer cells. This evidence concerns the gene ELOVL5 and breast carcinoma.